<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456844</url>
  </required_header>
  <id_info>
    <org_study_id>IM006-003</org_study_id>
    <nct_id>NCT02456844</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients</brief_title>
  <official_title>Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the Pharmacokinetics (PK) parameters of montelukast, flurbiprofen, midazolam,
      digoxin, pravastatin, and MTX when coadministered with BMS-986142.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Days 1 through 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration, AUC(0-T)</measure>
    <time_frame>Days 1 through 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time, AUC(INF)</measure>
    <time_frame>Days 1 through 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half-life (T-half)</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (parents only), CLT/F</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (For BMS-986142 only)</measure>
    <time_frame>Days 1 through 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate,Leucovorin and BMS-986142</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142</intervention_name>
    <description>Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose
Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose
Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose
Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose
Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose
BMS-986142: On Days 6 through 12.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate, Leucovorin and BMS-986142</intervention_name>
    <description>Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)
Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)
BMS-986142 on Days 6 through 10.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Groups 1 and 2:

          1. Written informed consent from all subjects.

          2. Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive

          3. Non-smokers.

          4. Normal renal function at screening as evidenced by an estimated glomerular filtration
             rate (GFR) of &gt; 90 mL/min/1.73 m2 .

          5. Subject reenrollment.

          6. Males who are sexually active with women of childbearing potential (WOCBP) must agree
             to follow instructions for method(s) of contraception for the duration of treatment
             with study drug plus 5 half-lives of BMS-986142.

          7. Male subjects must be willing to refrain from sperm donation during the entire study
             plus 5 half-lives of BMS-986142.

        Group 1 only:

          1. Healthy male and female (not of childbearing potential) subjects as determined by
             medical history, and clinical assessments.

          2. Women must have documented proof that they are not of childbearing potential and must
             not be breast feeding.

        Group 2 only:

        1. Healthy male subjects as determined by medical history, and clinical assessments.

        Exclusion Criteria:

          1. Administration of live vaccine including polio vaccine during the course of the study,
             12 weeks prior to the first dose of study drug, or 30 days after the last dose of
             study drug.

          2. Active tuberculosis (TB) requiring treatment within the previous 3 years.

          3. History of herpes zoster.

          4. Subjects who have experienced recent infection, upper respiratory infection,.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Hunt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPD</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

